Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Janux Therapeutics Inc (JANX)

Janux Therapeutics Inc (JANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 993,043
  • Shares Outstanding, K 60,148
  • Annual Sales, $ 10,590 K
  • Annual Income, $ -68,990 K
  • EBIT $ -144 M
  • EBITDA $ -153 M
  • 60-Month Beta 2.82
  • Price/Sales 93.16
  • Price/Cash Flow N/A
  • Price/Book 1.01

Options Overview Details

View History
  • Implied Volatility 71.63% (-6.29%)
  • Historical Volatility 232.47%
  • IV Percentile 10%
  • IV Rank 19.12%
  • IV High 181.74% on 11/25/25
  • IV Low 45.60% on 12/24/24
  • Expected Move (DTE 11) 2.04 (12.36%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 1,948
  • Volume Avg (30-Day) 2,366
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 37,509
  • Open Int (30-Day) 21,004
  • Expected Range 14.47 to 18.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 8
  • High Estimate -0.56
  • Low Estimate -0.78
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.51 +6.45%
on 12/03/25
35.34 -53.28%
on 11/26/25
-11.03 (-40.05%)
since 11/05/25
3-Month
15.51 +6.45%
on 12/03/25
35.34 -53.28%
on 11/26/25
-7.47 (-31.15%)
since 09/05/25
52-Week
15.51 +6.45%
on 12/03/25
68.99 -76.07%
on 12/06/24
-49.79 (-75.10%)
since 12/05/24

Most Recent Stories

More News
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated...

JANX : 16.51 (+0.67%)
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ET

JANX : 16.51 (+0.67%)
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 ...

JANX : 16.51 (+0.67%)
Janux Therapeutics Inc (JANX) Gets a Buy from Truist Financial

Truist Financial analyst initiated coverage with a Buy rating on Janux Therapeutics Inc yesterday and set a price target of $100.00. The company’s shares closed yesterday at $22.76.Elevate Your Investing...

JANX : 16.51 (+0.67%)
Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Janux Therapeutics Inc today. The company’s shares closed yesterday at $23.31.Elevate Your Investing Strategy: Take advantage...

JANX : 16.51 (+0.67%)
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases ...

JANX : 16.51 (+0.67%)
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux

JANX : 16.51 (+0.67%)
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth...

JANX : 16.51 (+0.67%)
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...

JANX : 16.51 (+0.67%)
Why Janux Therapeutics Crushed the Market Today

News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (NASDAQ: JANX) stock on Wednesday. The clinical-stage biotech's share price ended...

JANX : 16.51 (+0.67%)

Business Summary

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 17.24
2nd Resistance Point 16.89
1st Resistance Point 16.70
Last Price 16.51
1st Support Level 16.16
2nd Support Level 15.81
3rd Support Level 15.62

See More

52-Week High 68.99
Fibonacci 61.8% 48.56
Fibonacci 50% 42.25
Fibonacci 38.2% 35.94
Last Price 16.51
52-Week Low 15.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar